Drug Trial Radar · NCT00921375
Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia
Last checked: Nov 20, 2026Latest source record: Dec 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Feb 2010
Primary completion
Dec 2011
Study completion Jan 2012
Sponsor
- Lead sponsor
- Virchow GroupIndustry
- Sponsor type
- Industry
- First posted
- Jun 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 1 year, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, open-label, multicentre study. Hundred eligible patients with stage III or IV non-Hodgkin lymphoma (NHL) or acute lymphoblastic leukemia (ALL) with a peripheral white blood cell (WBC) count of \> 25,000/µL or any leukemia or lymphoma with plasma uric acid level of at least 8 mg/dL will be treated with rasburicase 0.20 mg/kg body weight intravenously for 4 days. The primary endpoints viz., the percentage of reduction in plasma uric acid at 4 hrs after uric acid-lowering therapy, plasma uric acid AUC 0-96 hr and incidence of adverse events will be assessed during 11 days study period.
Conditions
- Hyperuricemia
Interventions
TULYDrug
TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of reduction in plasma uric acid at 4 hrs after uric acid-lowering therapyTime frame: At the end of 4 hrs after initiation of uric acid lowering therapy; during 96 hrs of uric acid lowering therapy; Adverse events during the entire study period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dr. Raghunathrao
Hyd, Andhra Pradesh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.